Abstract
The appeal of using embryonic stem (ES) cells for regenerative medicine lies in their pluripotency and resulting ability to differentiate into all somatic cell types. While graft rejection remains the greatest hurdle to their use in the clinic, several approaches have been proposed to protect the allogeneic ES cell-derived grafts from host immunity: the creation of nuclear transfer human ES (hES) cell lines; the development of parthenogenic hES cells and iPS cells; the establishment of a bank of clinically-approved lines; the generation of hematopoietic chimerism and the induction of peripheral tolerance in recipients. Here, we discuss how the immune-privileged features of ES cells and tissues derived from them may influence these approaches and review the strategies and mechanisms involved in sustaining antigen-specific tolerance through interplay between dendritic cells (DC) and regulatory T cells (Treg). This overview therefore surveys prospects for developing novel regimes to prolong acceptance of ES cell-derived tissues with minimal use of immunosuppressive drugs.
Keywords: Embryonic stem cells, immune privilege, transplantation
Current Stem Cell Research & Therapy
Title: Embryonic Stem Cells: Overcoming the Immunological Barriers to Cell Replacement Therapy
Volume: 4 Issue: 1
Author(s): Kathy O. Lui, Herman Waldmann and Paul J. Fairchild
Affiliation:
Keywords: Embryonic stem cells, immune privilege, transplantation
Abstract: The appeal of using embryonic stem (ES) cells for regenerative medicine lies in their pluripotency and resulting ability to differentiate into all somatic cell types. While graft rejection remains the greatest hurdle to their use in the clinic, several approaches have been proposed to protect the allogeneic ES cell-derived grafts from host immunity: the creation of nuclear transfer human ES (hES) cell lines; the development of parthenogenic hES cells and iPS cells; the establishment of a bank of clinically-approved lines; the generation of hematopoietic chimerism and the induction of peripheral tolerance in recipients. Here, we discuss how the immune-privileged features of ES cells and tissues derived from them may influence these approaches and review the strategies and mechanisms involved in sustaining antigen-specific tolerance through interplay between dendritic cells (DC) and regulatory T cells (Treg). This overview therefore surveys prospects for developing novel regimes to prolong acceptance of ES cell-derived tissues with minimal use of immunosuppressive drugs.
Export Options
About this article
Cite this article as:
Lui O. Kathy, Waldmann Herman and Fairchild J. Paul, Embryonic Stem Cells: Overcoming the Immunological Barriers to Cell Replacement Therapy, Current Stem Cell Research & Therapy 2009; 4 (1) . https://dx.doi.org/10.2174/157488809787169093
DOI https://dx.doi.org/10.2174/157488809787169093 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Blood-Central Nervous System Barriers Actively Control Immune Cell Entry into the Central Nervous System
Current Pharmaceutical Design Pleiotropic Effects of Statins: Stabilization of the Vulnerable Atherosclerotic Plaque?
Current Pharmaceutical Design Mouse Models of Autoimmune Uveitis
Current Pharmaceutical Design Heart Failure Models: Traditional and Novel Therapy
Current Vascular Pharmacology Bacterial Toxins: Potential Weapons Against HIV Infection
Current Pharmaceutical Design Use of MHC II Structural Features in the Design of Vaccines for Organ-Specific Autoimmune Diseases
Current Pharmaceutical Design Novel Promising Therapeutic Agents in Multiple Sclerosis
Recent Patents on Inflammation & Allergy Drug Discovery Blood-Brain Barrier Transport of Cytokines: A Mechanism for Neuropathology
Current Pharmaceutical Design Clinical and Pharmacological Aspects of Inflammatory Demyelinating Diseases in Childhood: An Update
Current Neuropharmacology Designing Peptide Mimetics for the Treatment of Multiple Sclerosis
Mini-Reviews in Medicinal Chemistry A Common Pathway for All Autoimmune Diseases? The Unholy Alliance of Environment, Cell Death and Nucleic Acids
Current Immunology Reviews (Discontinued) Understanding Heterogeneity in Supplementation Effects of Selenium in Men: A Study of Stratification Variables and Human Genetics in a Prospective Sample from New Zealand
Current Pharmacogenomics and Personalized Medicine New Actors for the Immunological Mechanisms Involved in the Materno- Fetal Tolerance
Current Women`s Health Reviews Demonstration of Biological and Immunological Equivalence of a Generic Glatiramer Acetate
CNS & Neurological Disorders - Drug Targets Phosphonate Emerging Zinc Binding Group in Matrix Metalloproteinase Inhibitors
Current Drug Targets Editorial [Hot Topic: Anti-Neuroinflammatory Effects of Psychopharmaceuticals: Further than Monoamine Modulators (Guest Editor: Sadayuki Hashioka)]
Mini-Reviews in Medicinal Chemistry Indoxyl Sulfate: A Candidate Target for the Prevention and Treatment of Cardiovascular Disease in Chronic Kidney Disease
Current Drug Targets Renin-Angiotensin System in Central Nervous System Diseases and its Interaction with COVID-19
Current Medicinal Chemistry Leptin as a Novel Therapeutic Target for Immune Intervention
Current Drug Targets - Inflammation & Allergy Tyrphostins as Potential Therapeutic Agents for Acute Kidney Injury
Current Medicinal Chemistry